Myriad Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

• Myriad Genetics Inc (MYGN.OQ) reported a quarterly adjusted loss of 3 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -8 cents to -3 cents per share.

• Revenue fell 3.1% to $195.90 million from a year ago; analysts expected $200.56 million.

• Myriad Genetics Inc’s reported EPS for the quarter was breakeven results​.

• The company reported a quarterly loss of $100 thousand.

• Myriad Genetics Inc shares had fallen by 13.2% this quarter and lost 43.8% so far this year. FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 340.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS

• The current average analyst rating on the shares is “hold” and the breakdown of recommendations is 7 “strong buy” or “buy,” 6 “hold” and 4 “sell” or “strong sell.” The average consensus recommendation for the medical equipment, supplies & distribution peer group is also “hold”

• Wall Street’s median 12-month price target for Myriad Genetics Inc is $14.00 This summary was machine generated from LSEG data May 6 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Mar. 31 2025 -0.06 -0.03 Beat

Dec. 31 2024 0.03 0.03 Met

Sep. 30 2024 0.02 0.06 Beat

Jun. 30 2024 -0.01 0.05 Beat